This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hofmann, C.
Right arrow Articles by Strauss, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hofmann, C.
Right arrow Articles by Strauss, M.

 Previous Article  |  Next Article 

Journal of Virology, August 1999, p. 6930-6936, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Ovine Adenovirus Vectors Overcome Preexisting Humoral Immunity against Human Adenoviruses In Vivo

Christian Hofmann,1,* Peter Löser,1 Günter Cichon,2 Wolfgang Arnold,1,3 Gerald W. Both,4 and Michael Strauss1,5,6

HepaVec AG für Gentherapie,1 Max Delbrück Center for Molecular Medicine,2 Biomedizinischer Forschungscampus Berlin-Buch,3 and Humboldt University Berlin,5 13122 Berlin-Buch, Germany; Division of Molecular Science, CSIRO, North Ryde, New South Wales 2113, Australia4; and Division of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen, Denmark6

Received 4 February 1999/Accepted 4 May 1999

Recombinant human adenoviruses (hAd) have become widely used as tools to achieve efficient gene transfer. However, successful application of hAd-derived vectors in clinical trials is limited due to immunological and potential safety problems inherent in their human origin. In this study, we describe a recombinant ovine adenovirus (OAV) as an alternative vector for gene transfer in vivo. In contrast to an hAd vector, the OAV vector was not neutralized by human sera. An OAV vector which contained the cDNA of the human alpha 1-antitrypsin (hAAT) gene linked to the Rous sarcoma virus promoter was generated and administered systemically to mice. The level and duration of hAAT gene expression was similar to that achieved with an hAd counterpart in both immunocompetent and immunodeficient mice. However, the tissue distribution of the OAV vector differed from that observed for hAd vectors in that the liver was not the dominant target. Significantly, we demonstrated efficient gene transfer with the OAV vector into mice immunized with hAd vectors and vice versa. We also confirm that the immune response to a transgene product can prevent its functional expression following sequential application of a vector. Our results suggest a possible solution to endemic humoral immunity against currently used hAd vectors and should therefore have an impact on the design of improved gene therapy protocols utilizing adenovirus vectors.

* Corresponding author. Mailing address: HepaVec AG für Gentherapie, Robert-Rössle-Str. 10, D-13122 Berlin, Germany. Phone: 49 30 94892283 or 49 30 94892272. Fax: 49 30 94892913. E-mail: chofmann{at}hepavec.com.

Journal of Virology, August 1999, p. 6930-6936, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Schoenly, K. A., Weiner, D. B. (2008). Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business". J. Virol. 82: 3166-3180 [Full Text]  
  • Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., O'Brien, K. L., Carville, A., Mansfield, K. G., Goudsmit, J., Havenga, M. J. E., Barouch, D. H. (2007). Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. J. Virol. 81: 4654-4663 [Abstract] [Full Text]  
  • Hashimoto, M., Boyer, J. L., Hackett, N. R., Wilson, J. M., Crystal, R. G. (2005). Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity. Infect. Immun. 73: 6885-6891 [Abstract] [Full Text]  
  • Lemckert, A. A. C., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., Nanda, A., Ewald, B. A., Gorgone, D. A., Lifton, M. A., Goudsmit, J., Havenga, M. J. E., Barouch, D. H. (2005). Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity. J. Virol. 79: 9694-9701 [Abstract] [Full Text]  
  • Stone, D., Ni, S., Li, Z.-Y., Gaggar, A., DiPaolo, N., Feng, Q., Sandig, V., Lieber, A. (2005). Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector. J. Virol. 79: 5090-5104 [Abstract] [Full Text]  
  • Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J., Kaspers, J., Geelen, E., van der Helm, E., Lemckert, A., Gillissen, G., Verhaagh, S., Custers, J., Zuijdgeest, D., Berkhout, B., Bakker, M., Quax, P., Goudsmit, J., Havenga, M. (2004). Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5. J. Virol. 78: 13207-13215 [Abstract] [Full Text]  
  • Barouch, D. H., Pau, M. G., Custers, J. H. H. V., Koudstaal, W., Kostense, S., Havenga, M. J. E., Truitt, D. M., Sumida, S. M., Kishko, M. G., Arthur, J. C., Korioth-Schmitz, B., Newberg, M. H., Gorgone, D. A., Lifton, M. A., Panicali, D. L., Nabel, G. J., Letvin, N. L., Goudsmit, J. (2004). Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity. J. Immunol. 172: 6290-6297 [Abstract] [Full Text]  
  • Sumida, S. M., Truitt, D. M., Kishko, M. G., Arthur, J. C., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Koudstaal, W., Pau, M. G., Kostense, S., Havenga, M. J. E., Goudsmit, J., Letvin, N. L., Barouch, D. H. (2004). Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors. J. Virol. 78: 2666-2673 [Abstract] [Full Text]  
  • Barzon, L., Boscaro, M., Palu, G. (2004). Endocrine Aspects of Cancer Gene Therapy. Endocr. Rev. 25: 1-44 [Abstract] [Full Text]  
  • Loser, P., Hofmann, C., Both, G. W., Uckert, W., Hillgenberg, M. (2003). Construction, Rescue, and Characterization of Vectors Derived from Ovine Atadenovirus. J. Virol. 77: 11941-11951 [Abstract] [Full Text]  
  • Liu, X. S., Xu, Y., Hardy, L., Khammanivong, V., Zhao, W., Fernando, G. J. P., Leggatt, G. R., Frazer, I. H. (2003). IL-10 Mediates Suppression of the CD8 T Cell IFN-{gamma} Response to a Novel Viral Epitope in a Primed Host. J. Immunol. 171: 4765-4772 [Abstract] [Full Text]  
  • Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Bethune, M.-P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., Cecchini, M., Wetterwald, A., Sprangers, M., Lemckert, A., Ophorst, O., Koel, B., van Meerendonk, M., Quax, P., Panitti, L., Grimbergen, J., Bout, A., Goudsmit, J., Havenga, M. (2003). Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity. J. Virol. 77: 8263-8271 [Abstract] [Full Text]  
  • Kumin, D., Hofmann, C., Rudolph, M., Both, G. W., Loser, P. (2002). Biology of Ovine Adenovirus Infection of Nonpermissive Cells. J. Virol. 76: 10882-10893 [Abstract] [Full Text]  
  • van Olphen, A. L., Mittal, S. K. (2002). Development and Characterization of Bovine x Human Hybrid Cell Lines That Efficiently Support the Replication of both Wild-Type Bovine and Human Adenoviruses and Those with E1 Deleted. J. Virol. 76: 5882-5892 [Abstract] [Full Text]  
  • Xiang, Z., Gao, G., Reyes-Sandoval, A., Cohen, C. J., Li, Y., Bergelson, J. M., Wilson, J. M., Ertl, H. C. J. (2002). Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product. J. Virol. 76: 2667-2675 [Abstract] [Full Text]  
  • Soudais, C., Boutin, S., Hong, S. S., Chillon, M., Danos, O., Bergelson, J. M., Boulanger, P., Kremer, E. J. (2000). Canine Adenovirus Type 2 Attachment and Internalization: Coxsackievirus-Adenovirus Receptor, Alternative Receptors, and an RGD-Independent Pathway. J. Virol. 74: 10639-10649 [Abstract] [Full Text]  
  • Russell, W. C. (2000). Update on adenovirus and its vectors. J. Gen. Virol. 81: 2573-2604 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»